The Waters Centre for BioMedical Mass Spectrometry at the University of Warwick

April 21, 2009

Waters Corporation (Milford, Massachusetts) and the University of Warwick, Coventry and Warwickshire, England, signed a collaborative research agreement intended to support the growth, development and adoption of novel mass spectrometry (MS) technologies.

Waters Corporation (Milford, Massachusetts) and the University of Warwick, Coventry and Warwickshire, England, signed a collaborative research agreement intended to support the growth, development and adoption of novel mass spectrometry (MS) technologies. This agreement paves the way for research projects leading to meaningful impact for analysts using biomedical mass spectrometry, validated by peer-reviewed publications, presentations at international conferences, and an outreach education program.

At the core of the collaborative agreement is the establishment of “The Waters Centre for BioMedical Mass Spectrometry” at the University of Warwick, a center of excellence in state-of-the-art MS techniques. This center will offer scientists worldwide an accessible resource to enable the adoption of cutting-edge LC–MS-based techniques in life science.“I believe that this partnership between a proven technology leader and a leading research-focused University will provide a platform for the development of many exciting new projects,” said Prof. James Scrivens, Department of Biological Sciences, University of Warwick. “I look forward to being part of a team that delivers the benefits of our research to the wider community.”